The Division of Transplantation has earned acclaim from the international medical community for such breakthroughs as the UW-Belzer solution for organ preservation, research and clinical trials into the immunosuppressive drug mycophenolate mofetil, and improved surgical technqiues for pancreas transplantation.
Current laboratory research includes programs in organ preservation, the development of new immuosuppressants, gene therapy for diabetes as an alternative to pancreas transplantation, and induction of immunological tolerance to organ transplantation as an alternative to lifelong immunosuppression.
The Division of Transplantation directs the NIH-funded T32 Transplant Research Training Program for MDs and PhDs who are strongly motivated toward a career in transplant-related research.
Active Clinical Trials
The Transplant Clinical Trials Office can be contacted at 608-263-2565.
|A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
David P Foley, MD